Furthermore, representatives of both, bile acid analogues and non-steroidal FXR agonists like nidufexor (Chianelli et al., 2020) or tropifexor (Tully et al., 2017) are under clinical investigation for treatment of NAFLD and NASH (Mudaliar et al., 2013; Neuschwander-Tetri et al., 2015). Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.